Faculty of Medical Sciences
http://dr.lib.sjp.ac.lk/handle/123456789/5493
2023-12-22T18:31:13ZINJURY PATTERN AMONG PATIENTS WITH SELFINFLICTED CUT INJURIES PRESENTING TO THE ACCIDENT SERVICE UNIT OF NATIONAL HOSPITAL, SRI LANKA
http://dr.lib.sjp.ac.lk/handle/123456789/12411
INJURY PATTERN AMONG PATIENTS WITH SELFINFLICTED CUT INJURIES PRESENTING TO THE ACCIDENT SERVICE UNIT OF NATIONAL HOSPITAL, SRI LANKA
Goonewardene, A.D.; Jayakody, S.
2020-01-01T00:00:00ZChildhood Asthma and its Association with Selected Obstetric and Neonatal Factors among Children Aged 3 -10 Years in Tertiary Care Hospitals in Colombo District
http://dr.lib.sjp.ac.lk/handle/123456789/12410
Childhood Asthma and its Association with Selected Obstetric and Neonatal Factors among Children Aged 3 -10 Years in Tertiary Care Hospitals in Colombo District
Deen, F.A.H.; Kottahachchi, K.C.; Perera, S.S.; Dissanayake, D.M.O.C.; Jayakody, S.
2020-01-01T00:00:00ZComparing Traditional and Integrated Curricula on Physiology Knowledge Retention and Application
http://dr.lib.sjp.ac.lk/handle/123456789/12409
Comparing Traditional and Integrated Curricula on Physiology Knowledge Retention and Application
Fernando, S.; Ellawala, A.; Wijayasir, A.
Introduction: The Faculty of Medical Sciences revised its curriculum from traditional, subject-based, to
an integrated, system-based one in 2007. This study aimed to assess and compare the ability to retain
and apply knowledge in Physiology, among the last batch of students following the traditional curriculum
and the first batch following the integrated curriculum.
Methods: Twenty true/false type applied Physiology questions from the 2nd year examinations of the
two batches were administered separately when the students were in the final year. The marks were
compared with those obtained for the same questions at the 2nd year examination. The difference
between the two was considered the retention score. A SAQ comprising applied Physiology questions
was also administered to assess application ability and the scores were compared.
Results: A total of 152 and 132 participated from the batches following the traditional and integrated
curricula respectively. Both batches displayed a significant loss of knowledge by the final year (negative
retention score). The knowledge loss was lower in academically average and high performing students
of the integrated curriculum. Students following the integrated curriculum showed significantly higher
ability to apply Physiology knowledge to clinical problems.
Conclusion: The students following the integrated curriculum were better in applying physiology
knowledge to clinical scenarios and the retention of knowledge was also better among the average and
high performing students following the integrated curriculum.
2020-01-01T00:00:00ZTreatment of COVID-19: A review of emerging treatment
http://dr.lib.sjp.ac.lk/handle/123456789/12408
Treatment of COVID-19: A review of emerging treatment
Wanigatunge, C A; Munidasa, D; Uluwattage, W; Sathischandra, H; Rajapakse, S
COVID-19 has caused a devastating pandemic,
infecting 3,090,445 people and causing 217,769
deaths, as of 30 April, 2020. The current evidence
base for selected drugs repositioned to treat COVID19 are summarized here. Chloroquine (CQ) and
hydroxychloroquine (HCQ) block the entry of the
SARS-CoV-2 virus into cells and have immunomodulatory effects. Early, poor quality studies
pointed to benefit with CQ and HCQ treatment in
COVID-19 infection, but no further evidence supporting their use is available to date, and the drugs
cannot be recommended for treatment or prophylaxis. However, several countries use CQ or HCQ
for compassionate treatment. Lopinavir-ritonavir,
which is effective against HIV, was evaluated in one
clinical trial which showed no benefit. Remdesivir, a
drug developed for EBOLA, has been shown to have
in-vitro efficacy against SARS-CoV-2, and the treatment has been used on compassionate grounds in
severe cases. Limited studies have shown clinical
improvement with remdesivir which is approved for
emergency use in severe COVID-19. The RNA
polymerase inhibitor favipiravir has been shown to
improve clinical features, hasten viral clearance, and
improve HRCT findings. Corticosteroids have shown
no benefit. Trials are underway with the IL-6 receptor
blocking monoclonal antibody tocilizumab, with
retrospective data showing reduction in inflammatory markers and clinical improvement. Convalescent plasma has been shown to be of some
benefit in severe cases of SARS, MERS and H1N1
influenza, and is recommended by the FDA for those
with serious or immediately life-threatening infection
with COVID-19. Several large randomized controlled
trials are underway, evaluating these repositioned
therapies as well as many other treatments. No
effective specific treatments are available for COVID19 infection as yet
2020-01-01T00:00:00Z